Citeline

🔍 Is your patient recruitment strategy truly data-driven? 🔗 Register now: https://vist.ly/4b6gv In the second of our three-part webinar series, Roadmap to Patient Recruitment Success, discover how feasibility data can unlock scalable, tailored recruitment strategies. Join experts Lindsay Stahl and Matt Holms, MBA in this webinar. 📅 October 22 | 🎟️ Free to attend ———— Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. #ClinicalTrials #PatientRecruitment #CitelineWebinar #LifeSciences

📄 Your source of truth for clinical trial disclosure: https://vist.ly/4b4jt At Citeline, our content ensures full audit readiness with direct links to source materials for added context. 🧠 Dive deeper by watching sessions #EXTRA2025 featuring expert insights and forward-looking analysis from leaders in clinical trial transparency. Learn how Citeline empowers your team with trusted, actionable insights: https://vist.ly/4b4jt ———— Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

https://vist.ly/4a2p3 | Join Arran Carter, Senior Product Manager at Citeline, Jaclyn Spedaliere, VP of Regulatory Sales at Citeline and Radek Grabowski, Head of Registries, Clinical Trial Transparency at AstraZeneca on Tuesday, Oct 21 at 11:45 CET at Clinical Data Disclosure Europe. We're diving into a detailed analysis of EU CTR and CTIS Compliance Requirements, simplifying the complex, and helping you navigate the rapidly evolving landscape of the EU centralised clinical trial platform. Be ready to adapt to new regulations and build stronger connections across member states. Get prepped to tackle any RFIs from regulatory authorities – all in less than an hour. Our Citeline experts want to help you save time and stay ahead in the pharmaceutical and medtech markets as regulations shift. We're with you every step of the way, offering expert insights you need to move forward. Keep pace with change. Follow Citeline. Let our robust network of industry knowledge and cutting-edge market intelligence help you make proactive decisions that matter.

It’s the final days of ESMO - don’t miss the insights! https://vist.ly/4azt5 As ESMO 2025 wraps up, Scrip’s expert coverage continues with late-breaking data, R&D leader interviews, and commercial impact analysis.
 Your free trial gives you full access to all the post-event reporting. Catch up on the biggest stories shaping oncology’s future.
 👉 https://vist.ly/4azt8 #ESMO2025 #ScripCoverage ESMO - European Society for Medical Oncology


Immerse yourself in the dynamic world of generics, biosimilars, and value-added medicines! Check out our infographic preview of Generics Bulletin’s Top 50 2025: https://vist.ly/4aymh ——— Ready to delve deeper? Follow Citeline for insightful analysis on pharma, biotech, medtech and consumer health. Download our app now: https://vist.ly/4aymd to stay updated.

Gene therapy continues to build momentum in oncology: https://vist.ly/4axtx In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year. What does this signal for the future of advanced therapies? Explore the latest trends in our Gene, Cell, and RNA Therapy Landscape Report, featuring industry-leading data from Pharmaprojects and American Society of Gene & Cell Therapy. Download the full report: https://vist.ly/4axtx

#SmallBiotechsBigDecisions launches a new episode on early CRO engagement. Listen here: https://vist.ly/4axgv Dive into game-changing strategies to optimize funding, trial design, and patient recruitment. Discover how the right #CRO partnership can streamline clinical trials and reduce risk. ✔️ Watch the full episode: https://vist.ly/4axgv ✔️ Listen on the go: https://lnkd.in/gJwViHHV ✔️ Explore all episodes: https://vist.ly/4axgz ———— Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

ESMO 2025 is in full swing! Stay up to date with Scrip’s real-time reporting from Berlin. https://vist.ly/4avq3 Our editorial team is on the ground, delivering daily updates, exclusive interviews, and commercial impact analysis.
 Don’t miss a moment - sign up for your free trial and get all the news and analysis as it happens. 
👉 https://vist.ly/4avq4 #ESMO2025 #ScripCoverage ESMO - European Society for Medical Oncology


Immerse yourself in the dynamic world of generics, biosimilars, and value-added medicines! Check out our infographic preview of Generics Bulletin’s Top 50 2025: https://vist.ly/4avpz ——— Ready to delve deeper? Follow Citeline for insightful analysis on pharma, biotech, medtech and consumer health. Download our app now: https://vist.ly/4avpw to stay updated.

Step into the future of obesity management with Dave Wallace, Generics Bulletin Executive Editor, as he illuminates life-changing generic alternatives of weight-loss medication in a recent Daily Mail - UK News piece. https://vist.ly/4ava7 (subscription required). #Semaglutide #Wegovy #Ozempic _____ Follow Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: https://vist.ly/4avaa